1-3 of 3
James Slack
Close
Sort by
Journal Articles

RNAi screening of the kinome with cytarabine in leukemias

Raoul Tibes, James M. Bogenberger, Leena Chaudhuri, R. Tanner Hagelstrom, Donald Chow, Megan E. Buechel, Irma M. Gonzales, Tim Demuth, James Slack, Ruben A. Mesa, Esteban Braggio, Hongwei H. Yin, Shilpi Arora, David O. Azorsa
Journal: Blood
Blood (2012) 119 (12): 2863–2872.
https://doi.org/10.1182/blood-2011-07-367557
Published: 2012
Includes: Supplemental data
Journal Articles

Minimal Residual Disease (MRD) and Risk of Relapse in Acute Promyelocytic Leukemia (APL): Insights from the North American Intergroup Phase III Trial C9710.

Wendy Stock, MD, Richard Harvey, MD, Barry Moser, PhD, Dorie Sher, BS, Esther Schachter-Tokarz, BS, Matthew Myers, BS, James Slack, MD, Bayard Powell, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD, Martin S. Tallman, MD, Frederick R. Appelbaum, MD, James Feusner, MD, Cheryl Willman, MD, Robert Gallagher, MD
Journal: Blood
Blood (2006) 108 (11): 494.
https://doi.org/10.1182/blood.V108.11.494.494
Published: 2006
Journal Articles

First Report of the Phase III North American Trial of Decitabine in Advanced Myelodysplastic Syndrome (MDS).

Hussain Saba, Craig Rosenfeld, Jean-Pierre Issa, John DiPersio, Azra Raza, Virginia Klimek, James Slack, Carlos de Castro, Karl Mettinger, Hagop Kantarjian
Journal: Blood
Blood (2004) 104 (11): 67.
https://doi.org/10.1182/blood.V104.11.67.67
Published: 2004